Drug company MannKind Corp. (MNKD) Monday reported fourth-quarter net loss to common shares of $51.8 million or $0.23 per share, compared with net loss of $36 million or $0.30 per share in the prior year. Loss per share results for the reporting quarter reflect a higher share count.
On average, 8 analysts polled by Thomson Reuters expected a loss of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.
Research and development expenses for the quarter escalated to $25 million from $20 million a year ago, reflecting increased clinical trial related activities. The company also incurred other expenses of $13 million during the quarter.
Mannkind did not generate any revenues for the quarter, just as in the prior year.
Cash and cash equivalents were $61.8 million at December 2012.
MannKind Corp. focuses on the development of therapeutic products for patients with diseases such as diabetes and cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.